Seeking for partners on drug discovery programs based on our Nanocyclix platform as next-generation kinase inhibitors.

Using its Nanocyclix® technology, Oncodesign identifies small macrocyclic molecules capable of inhibiting both known and unexplored kinases in a powerful and targeted manner. 

A large variety of kinase inhibitors are thus explored continuously, and the most promising inhibitor/targeted kinase combinations are selected for more in depth investigations. 

Oncodesign has built a project portfolio with promising potential to treat diseases with very substantial unmet medical needs. This portfolio contains both molecules already at an advanced stage of clinical development and molecules at an earlier stage of development.

Connect with Dr. Jan Hoflack - Chief Scientific Officer and Executive Director, Head of Biotech Business Unit – to discuss Oncodesign’s partnering and licensing opportunities:

• A RIPK2 inhibitor at pre-IND stage with potential in multiple auto-immune and inflammatory indications is presented for partnering/out-licensing
• Lead stage programs available for partnership on attractive kinases: MNK1/2, ALK1, ALK2, CK1, Pikfyve, CDK7, PI3K, RET, ...
• Nanocyclix based partnerships on your kinase targets

This email address is being protected from spambots. You need JavaScript enabled to view it.

Are you looking for an innovation-based solutions and expertise provider in Drug Discovery?

Oncodesign is offering DRIVE-IDDS™ an Integrated Drug Discovery Services for the discovery of new chemical entities from hits finding to clinical candidate as a one-stop-shop.

Fabrice Viviani - General Manager and Senior Executive Vice-President, Head of Oncodesign Service Business Unit - will attend Biotech Showcase and JP Morgan Healthcare Conference. He will be pleased to introduce our technology platforms supporting translational research from the early stages of the drug discovery process up to clinical candidate generation - a real driver of innovation, acceleration & success for your NCE programs.

This email address is being protected from spambots. You need JavaScript enabled to view it.